JPMorgan Chase Just Recommended Buying PepsiCo in 2026. Here Are the Tailwinds Buoying the Stock.

PepsiCo will cut nearly 20% of its product portfolio by early 2026—roughly 12 of its ~60 main brands—as part of a broader push to shed lagging labels, trim costs and boost margins, a move that appears to reflect constructive engagement with activist Elliott Investment Management. J.P. Morgan analyst Andrea Teixeira upgraded the stock to overweight and raised her price target to $164 (implying ~10% upside), while Elliott has praised the company’s focus on innovation and cost discipline; further structural actions such as divesting bottling or legacy units (e.g., parts of Quaker) remain possible. Management’s refreshed value proposition and improving snack sales should help PepsiCo pursue its 2026 organic sales target of 2–4%, creating multiple potential catalysts for the stock into 2026, though execution and the scope of divestitures will determine the ultimate impact.

Analysis

PepsiCo announced it will eliminate nearly 20% of its product portfolio by early 2026—roughly 12 brands out of about 60—as part of a broader program to shed lagging labels, trim costs and improve margins. J.P. Morgan analyst Andrea Teixeira upgraded PEP to overweight and raised her price target from $151 to $164, implying roughly 10.2% upside from the referenced closing price, signaling a sell-side endorsement that could act as a near-term catalyst.

The company’s move appears to reflect constructive engagement with activist Elliott Investment Management, which has praised PepsiCo’s emphasis on innovation and cost discipline; management previously discussed divesting North American bottling and could pursue legacy asset sales such as parts of Quaker Oats. Removing underperforming brands should reduce operating expenses, free capacity for higher-return innovation and boost operating margins if execution aligns with projections.

PepsiCo is also refreshing its value proposition and is seeing improving snack sales, which supports management’s 2026 organic sales target of 2%–4%; hitting the high end would materially de-risk the upside case. Key risks are execution of brand rationalization, the scope/timing of any divestitures and whether cost savings translate into sustained margin expansion, so the current market signal is moderately positive but contingent on follow-through.

Key Decisions for Investors

• Consider a measured accumulation of PEP to capture potential upside from the portfolio pruning and the J.P. Morgan upgrade, but limit position size until management announces the specific brands and quantified cost-savings targets
• Monitor near-term catalysts closely—public list of brands to be cut, any announcement on bottling or Quaker-related divestitures, quarterly organic sales and margin trajectories—and be prepared to re-rate the position if results miss the stated 2%–4% organic growth goal
• Use tactical downside protection around major corporate events (protective puts or collars) rather than outright large sells, given the constructive activist relationship but material execution risk